Background—The risk of ischemic events is high, both early and late after acute coronary
syndromes (ACS). We examine the benefits and risks associated with the use of adding …

Background Clopidogrel and aspirin are widely used for patients with acute coronary
syndromes and those undergoing percutaneous coronary intervention (PCI). However …

Background Despite current treatments, patients who have acute coronary syndromes
without ST-segment elevation have high rates of major vascular events. We evaluated the …

Background—We studied the benefits and risks of adding clopidogrel to different doses of
aspirin in the treatment of patients with acute coronary syndrome (ACS). Methods and …

Background Despite improvements in the emergency treatment of myocardial infarction (MI),
early mortality and morbidity remain high. The antiplatelet agent clopidogrel adds to the …

Objectives: We sought to evaluate the long-term cost-effectiveness of clopidogrel for up to
one year after an acute coronary syndrome (ACS) without ST-segment elevation …

Background—The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial
demonstrated that clopidogrel, given early and continued long term, was superior to placebo …

Context It is unknown whether patients are at increased short-term risk for adverse events
following clopidogrel cessation. Objective To assess the rates of adverse events after …

Antiplatelet agents are central to the treatment and prevention of cardiovascular disease.
Although aspirin is the most widely used agent, randomized trials have assessed whether …

Summary Abstract Clopidogrel (Plavix®, Iscover®) selectively and irreversibly inhibits
adenosine diphosphate (ADP)-induced platelet aggregation. Long-term administration of …